Carl Ola Landgren: With Minimal Residual Disease (MRD) as an early endpoint for accelerated approval of new multiple myeloma drugs, patients access to new therapies will be much quicker

Carl Ola Landgren, Chief of the Myeloma Division and Translational Clinical Oncology Program at Sylvester Comprehensive Cancer Center, shared a post on X/Twitter:

“With Minimal Residual Disease (MRD) as an early endpoint for accelerated approval of new multiple myeloma drugs, patients’ access to new therapies will be much quicker.

Instead of waiting for 10-15 years, new drugs can be available in 3-5 years. Here is how it works.”

Source: Carl Ola Landgren/X